---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-025047"
form_type: "8-K"
ticker: "INSM"
cik: "0001104506"
company_name: "INSMED Inc"
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T04:50:11.762170+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Insmed Q1 ARIKAYCE revenue $75.5M (+16%); TPIP PH-ILD shows strong clinical worsening signal

## Summary
- ARIKAYCE Q1 revenue $75.5M, up 16% YoY; net loss $157.1M ($1.06/share) vs $159.8M ($1.17) prior year.
- TPIP Phase 2 PH-ILD: 79.3% reached max 640µg dose; clinical worsening 10.3% vs 50% placebo (p=0.0164).
- TPIP Phase 2 PAH blinded: first 40 patients showed mean PVR reduction 19.9%, 6MWD +43 meters.
- Brensocatib ASPEN topline data expected latter part of Q2 2024; 2024 ARIKAYCE guidance $340M-$360M.
- Cash $595.7M at March 31, 2024; company plans Phase 3 for TPIP in PH-ILD in 2025.

## SEC filing metadata
- accession: 0001140361-24-025047
- form_type: 8-K
- ticker: INSM
- cik: 0001104506
- company_name: INSMED Inc
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1104506/000114036124025047/0001140361-24-025047-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1104506/000114036124025047/ef20028736_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-025047
- JSON: https://secwatch.observer/filing/0001140361-24-025047.json
- Plain text: https://secwatch.observer/filing/0001140361-24-025047.txt

## Key facts
- Earnings Releases
  INSMED Inc updated its the first quarter ended March 31, 2024 guidance (reaffirmed).
  - Period: the first quarter ended March 31, 2024
  - Guidance: reaffirmed
  - Result: reported results
  source text: On May 9, 2024, Insmed Incorporated (the “Company”) issued a press release regarding its financial results for the three months ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1104506/000114036124025047/0001140361-24-025047-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.